New drug aims to shrink nasal polyps without surgery

NCT ID NCT07520162

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a drug called tezepelumab in 230 Chinese adults with chronic sinusitis and nasal polyps. Participants receive injections every four weeks for six doses. Researchers will measure changes in polyp size and nasal congestion over 24 weeks to see if the treatment helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tezepelumab (also called TEZSPIRE®)
What this could lead to
If successful, this could provide a new treatment option for Chinese adults with nasal polyps, reducing polyp size and easing congestion without surgery.
What could go wrong
This is an early-phase, single-arm study with no placebo group, so results may not prove the drug works better than no treatment. Side effects are possible, and the study is limited to Chinese participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100191, China

  • Research Site

    RECRUITING

    Beijing, 100730, China

  • Research Site

    NOT_YET_RECRUITING

    Bengbu, China

  • Research Site

    RECRUITING

    Cangzhou, 061000, China

  • Research Site

    NOT_YET_RECRUITING

    Changchun, China

  • Research Site

    RECRUITING

    Changsha, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, China

  • Research Site

    RECRUITING

    Chengdu, 610021, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610041, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, China

  • Research Site

    NOT_YET_RECRUITING

    Chongqing, China

  • Research Site

    RECRUITING

    Foshan, 528000, China

  • Research Site

    RECRUITING

    Fuzhou, 350005, China

  • Research Site

    NOT_YET_RECRUITING

    Guiyang, 550044, China

  • Research Site

    NOT_YET_RECRUITING

    Hefei, 230601, China

  • Research Site

    NOT_YET_RECRUITING

    Hefei, China

  • Research Site

    NOT_YET_RECRUITING

    Hohhot, China

  • Research Site

    RECRUITING

    Huaian, 223300, China

  • Research Site

    NOT_YET_RECRUITING

    Kunming, China

  • Research Site

    RECRUITING

    Lanzhou, 730030, China

  • Research Site

    RECRUITING

    Nanchang, China

  • Research Site

    NOT_YET_RECRUITING

    Nanning, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    RECRUITING

    Qingdao, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, China

  • Research Site

    RECRUITING

    Shenzhen, 518039, China

  • Research Site

    NOT_YET_RECRUITING

    Shijiazhuang, 50051, China

  • Research Site

    RECRUITING

    Taiyuan, 030001, China

  • Research Site

    RECRUITING

    Taizhou, 225300, China

  • Research Site

    RECRUITING

    Tianjin, China

  • Research Site

    RECRUITING

    Ürümqi, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430022, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuhu, 241004, China

  • Research Site

    NOT_YET_RECRUITING

    Xi'an, 710004, China

  • Research Site

    RECRUITING

    Yangzhou, 225000, China

  • Research Site

    RECRUITING

    Zibo, 255036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.